This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
ZC3H14 Polyclonal Antibody
catalog :
PA5-87844
quantity :
100 uL
price :
US 464.00
clonality :
polyclonal
host :
domestic rabbit
conjugate :
nonconjugated
reactivity :
human
application :
western blot, ELISA
product information
Product Type :
Antibody
Product Name :
ZC3H14 Polyclonal Antibody
Catalog # :
PA5-87844
Quantity :
100 uL
Price :
US 464.00
Clonality :
Polyclonal
Purity :
Affinity Chromatography
Host :
Rabbit
Reactivity :
Human
Applications :
ELISA: 1 ug/mL, Western Blot: 1:500-1:2,000
Species :
Human
Isotype :
IgG
Storage :
-20 C, Avoid Freeze/Thaw Cycles
Description :
ZC3H14 belongs to the ZC3H14 family.It contains 2 C3H1-type zinc fingers. ZC3H14 binds the polyadenosine RNA oligonucleotides.
Immunogen :
Recombinant fusion protein containing a sequence corresponding to amino acids 1-306 of human ZC3H14 (NP_9975452)
Format :
Liquid
Applications w/Dilutions :
ELISA: 1 ug/mL, Western Blot: 1:500-1:2,000
Aliases :
1010001P15Rik; 1700016A15Rik; 2700069A02Rik; AU014748; FLJ11806; Mammalian suppressor of tau pathology-2; MSUT-2; Npuk68; nuclear protein UKp68; nuclear protein UKp83/UKp68; NY-REN-37; Renal carcinoma antigen NY-REN-37; SUT2; UKp68; Zc3h14; Zinc finger CCCH domain-containing protein 14; zinc finger CCCH type containing 14; zinc finger CCCH-type containing 14
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com81 Wyman Street
Waltham, MA USA 02451
800-678-5599
headquarters: USA
questions and comments
